NewLink Genetics Corporation appointed Mr. Brian Wiley as Vice President of Business Development. In addition to business development responsibilities, Mr. Wiley will lead the commercialization strategy and pre-commercial activities for the company's HyperAcute Pancreas Immunotherapy, algenpantucel-L. Most recently, Brian was with key roles in both the sale of Gloucester Pharmaceuticals to Celgene Corporation and the purchase of Abraxis Health by Celgene.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | +2.67% | -13.48% | -51.57% |
06-04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
05-15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.57% | 12.17M | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- NewLink Genetics Corporation Appoints Brian Wiley as Vice President of Business Development